Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

Completed · Phase 1

Conditions studied: Breast Cancer, Lung Cancer, Ovarian Cancer

In brief

RATIONALE: Vaccines may make the body build an immune response to tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus sargramostim in treating patients who have stage III or stage IV cancer.

Key facts

Study ID

NCT00005023

Run by

University of Washington

Starts

1999-03-01

Expected to finish

2001-01-01

Last updated by the study team

2017-11-30

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Washington School of Medicine — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.